28657-80-9

• 常用中文名：西诺沙星
• 常用英文名：Cinoxacin
• CAS号：28657-80-9
• 分子式：C₁₂H₁₀N₂O₅
• 分子量：262.218
• 相关类别： 原料药 人工合成抗感染类药 喹诺酮类药
• 发布时间：2018-07-08 20:58:39
• 更新时间：2026-06-30 19:09:56
• Cinoxacin是一种老的合成的喹诺酮类抗生素, 与Oxolinic acid和 Nalidixic acid活性相似。

名称

• 中文名: 西诺沙星
• 英文名: cinoxacin
• 中文别名: 辛草酸; 西诺沙星Cinoxacin; 甲醇中西诺沙星; 乙腈(含DMSO)中西诺沙星; 西诺沙星溶液,1000PPM; 化合物：Cinoxacin; 新恶酸包装; 甲醇/二甲基亚砜中西诺沙星溶液,1000ΜG/ML; 化合物:Cinoxacin; 西诺沙星溶液, 100PPM; 西诺沙星,10 MM DMSO 溶液; 1-乙基-4-氧代-1,4-二氢-[1,3]二氧杂戊环并[4,5-G]噌啉-3-羧酸; 西诺沙星 28-9; 甲醇中西诺沙星溶液标准物质; 西诺沙星标准品; 新恶酸; 恶喹唑乙酸
• 英文别名: Cinobactin; 1-ethyl-4-oxo-1,4-dihydro-[1,3]dioxolo[4,5-g]cinnoline-3-cboxylic acid; cinobac; 1-ETHYL-1,4-DIHYDRO-4-OXO[1,3]DIOXOLO[4,5-G]CINNOLINE-3-CBOXYLIC ACID; Clinoxacin; Terbinafine Impurity 34; Azolinic Acid; CINOXACIN; Cinoxacin, 10 mM in DMSO; 3)dioxolo(4,5-g)cinnoline-3-cboxylicacid,1,4-dihydro-1-ethyl-4-oxo-(; 1-ethyl-1,4-dihydro-4-oxo-{1,3}dioxolo{4,5:g}cinnoline-3-carboxylic acid; Cinoxacin in Acetonitrile(DMSO); 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; EINECS 249-133-8; [1,3]Dioxolo[4,5-g]cinnoline-3-cboxylic acid, 1-ethyl-1,4-dihydro-4-oxo; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; TIMTEC-BB SBB003082; Cinoxacin Solution in Methanol/DMSO, 1000μg/mL; Cinoxacin in Methanol; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-cboxylic acid; Cinoxacine; Compound; Cinoxacinum; Cinobac; 1-ethyl-4-oxo-1,4-dihydro-[1,3]dioxolo[4,5-g]cinnoline-3-carboxilic acid; Cinoxacin（28-9）; MFCD00056776; CINOXACIN //BP; 1-ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; Cinoxacin Solution, 1000ppm; 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-cboxylicacid; Cinoxacino; Cinoxacin (Cinobac

物化性质

• 密度: 1.6±0.1 g/cm3
• 沸点: 517.2±60.0 °C at 760 mmHg
• 熔点: 210 °C
• 分子式: C₁₂H₁₀N₂O₅
• 分子量: 262.218
• 闪点: 266.6±32.9 °C
• 精确质量: 262.058960
• PSA: 90.65000
• LogP: 0.35
• 蒸汽压: 0.0±1.4 mmHg at 25°C
• 折射率: 1.709
• 储存条件:

  密闭于阴凉干燥环境中

• 稳定性:

  遵照规定使用和储存则不会分解。

• 分子结构:

  1、 摩尔折射率：62.35

  2、 摩尔体积（m³/mol）：159.7

  3、 等张比容（90.2K）：454.9

  4、 表面张力（dyne/cm）：65.7

  5、 极化率（10 ^-24cm ³）：24.72

• 计算化学:

  1.疏水参数计算参考值（XlogP）:2.1

  2.氢键供体数量:1

  3.氢键受体数量:7

  4.可旋转化学键数量:2

  5.互变异构体数量:无

  6.拓扑分子极性表面积88.4

  7.重原子数量:19

  8.表面电荷:0

  9.复杂度:449

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：无可用

  2. 密度（g/mL,25/4℃）：无可用

  3. 相对蒸汽密度（g/mL,空气=1）：无可用

  4. 熔点（ºC）：无可用

  5. 沸点（ºC,常压）：无可用

  6. 沸点（ºC,5.2kPa）：无可用

  7. 折射率：无可用

  8. 闪点（ºC）：无可用

  9. 比旋光度（º）：无可用

  10. 自燃点或引燃温度（ºC）：无可用

  11. 蒸气压（kPa,25ºC）：无可用

  12. 饱和蒸气压（kPa,60ºC）：无可用

  13. 燃烧热（KJ/mol）：无可用

  14. 临界温度（ºC）：无可用

  15. 临界压力（KPa）：无可用

  16. 油水（辛醇/水）分配系数的对数值：无可用

  17. 爆炸上限（%,V/V）：无可用

  18. 爆炸下限（%,V/V）：无可用

  19. 溶解性：无可用

生物活性

• 描述: Cinoxacin是一种老的合成的喹诺酮类抗生素, 与Oxolinic acid和 Nalidixic acid活性相似。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染

毒性和生态

生态学数据: 该物质对环境可能有危害，对水体应给予特别注意。 CHEMICAL IDENTIFICATION RTECS NUMBER : JI4640000 CHEMICAL NAME : (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1,4-dihydro-1-ethyl-4-oxo- CAS REGISTRY NUMBER : 28657-80-9 LAST UPDATED : 199612 DATA ITEMS CITED : 11 MOLECULAR FORMULA : C12-H10-N2-O5 MOLECULAR WEIGHT : 262.24 WISWESSER LINE NOTATION : T C566 DO FO JNN MV EHJ J2 LVQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3610 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1380 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 860 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2330 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 900 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 850 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness Lungs, Thorax, or Respiration - respiratory depression REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 8050 mg/kg/5W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - changes in bladder weight Endocrine - changes in thymus weight REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),406,1980 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 3150 mg/kg SEX/DURATION : male 63 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),484,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 4 gm/kg SEX/DURATION : male 9 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - other measures of fertility REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),484,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1100 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),484,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 550 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 4),484,1980

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危险品运输编码: NONH for all modes of transport
• RTECS号: JI4640000
• 海关编码: 2934999090

合成路线

74-96-4 90447-46-4 5137-55-3 ~% 28657-80-9

文献：Veb Arzneimittelwerk Dresden Patent: US4495351 A1, 1985 ;

海关

海关编码	2934999090
中文概述	2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%